Atorvastatin/aspirin/metoprolol/ramipril - Zydus Cadila

Drug Profile

Atorvastatin/aspirin/metoprolol/ramipril - Zydus Cadila

Latest Information Update: 07 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cadila Healthcare; Zydus Cadila
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Class II antiarrhythmics; Fatty acids; Heptanoic acids; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Propanolamines; Pyrroles; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Ischaemic heart disorders

Most Recent Events

  • 07 Aug 2015 No recent reports on development identified - Phase-III for Ischaemic heart disorders in India (PO)
  • 26 Mar 2010 Cadila Healthcare and Zydus Cadila complete a phase III trial in Ischaemic heart disorders in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top